92 related articles for article (PubMed ID: 16652383)
1. Genistein-induced neuroendocrine differentiation of prostate cancer cells.
Pinski J; Wang Q; Quek ML; Cole A; Cooc J; Danenberg K; Danenberg PV
Prostate; 2006 Aug; 66(11):1136-43. PubMed ID: 16652383
[TBL] [Abstract][Full Text] [Related]
2. Protein tyrosine phosphatase PTP1B is involved in neuroendocrine differentiation of prostate cancer.
Wu C; Zhang L; Bourne PA; Reeder JE; di Sant'Agnese PA; Yao JL; Na Y; Huang J
Prostate; 2006 Aug; 66(11):1125-35. PubMed ID: 16652382
[TBL] [Abstract][Full Text] [Related]
3. Gene profiling and pathway analysis of neuroendocrine transdifferentiated prostate cancer cells.
Mori R; Xiong S; Wang Q; Tarabolous C; Shimada H; Panteris E; Danenberg KD; Danenberg PV; Pinski JK
Prostate; 2009 Jan; 69(1):12-23. PubMed ID: 18814146
[TBL] [Abstract][Full Text] [Related]
4. Interferon-gamma induces neuroendocrine-like differentiation of human prostate basal-epithelial cells.
Untergasser G; Plas E; Pfister G; Heinrich E; Berger P
Prostate; 2005 Sep; 64(4):419-29. PubMed ID: 15800938
[TBL] [Abstract][Full Text] [Related]
5. A concentrated aglycone isoflavone preparation (GCP) that demonstrates potent anti-prostate cancer activity in vitro and in vivo.
Bemis DL; Capodice JL; Desai M; Buttyan R; Katz AE
Clin Cancer Res; 2004 Aug; 10(15):5282-92. PubMed ID: 15297432
[TBL] [Abstract][Full Text] [Related]
6. Vasoactive intestinal peptide induces neuroendocrine differentiation in the LNCaP prostate cancer cell line through PKA, ERK, and PI3K.
Gutiérrez-Cañas I; Juarranz MG; Collado B; Rodríguez-Henche N; Chiloeches A; Prieto JC; Carmena MJ
Prostate; 2005 Apr; 63(1):44-55. PubMed ID: 15468165
[TBL] [Abstract][Full Text] [Related]
7. Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible: implications for prostate cancer progression.
Cox ME; Deeble PD; Lakhani S; Parsons SJ
Cancer Res; 1999 Aug; 59(15):3821-30. PubMed ID: 10447001
[TBL] [Abstract][Full Text] [Related]
8. Activation of the Erk mitogen-activated protein kinase pathway stimulates neuroendocrine differentiation in LNCaP cells independently of cell cycle withdrawal and STAT3 phosphorylation.
Kim J; Adam RM; Freeman MR
Cancer Res; 2002 Mar; 62(5):1549-54. PubMed ID: 11888934
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory effect of IL-6-induced neuroendocrine cells on prostate cancer cell proliferation.
Wang Q; Horiatis D; Pinski J
Prostate; 2004 Nov; 61(3):253-9. PubMed ID: 15368468
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression.
Lee SO; Chun JY; Nadiminty N; Lou W; Gao AC
Prostate; 2007 May; 67(7):764-73. PubMed ID: 17373716
[TBL] [Abstract][Full Text] [Related]
11. Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells.
Yuan TC; Veeramani S; Lin MF
Endocr Relat Cancer; 2007 Sep; 14(3):531-47. PubMed ID: 17914087
[TBL] [Abstract][Full Text] [Related]
12. Transdifferentiation of prostate cancer cells to a neuroendocrine cell phenotype in vitro and in vivo.
Burchardt T; Burchardt M; Chen MW; Cao Y; de la Taille A; Shabsigh A; Hayek O; Dorai T; Buttyan R
J Urol; 1999 Nov; 162(5):1800-5. PubMed ID: 10524938
[TBL] [Abstract][Full Text] [Related]
13. A new screening system for proliferation-independent anti-cancer agents.
Horiatis D; Wang Q; Pinski J
Cancer Lett; 2004 Jul; 210(1):119-24. PubMed ID: 15172129
[TBL] [Abstract][Full Text] [Related]
14. Involvement of cholesterol-rich lipid rafts in interleukin-6-induced neuroendocrine differentiation of LNCaP prostate cancer cells.
Kim J; Adam RM; Solomon KR; Freeman MR
Endocrinology; 2004 Feb; 145(2):613-9. PubMed ID: 14563701
[TBL] [Abstract][Full Text] [Related]
15. [The influence of neuroendocrine differentiation on the growth and androgen receptor expression of prostate carcinoma cells].
Song Y; Wu G; Xin DQ; Na YQ
Zhonghua Wai Ke Za Zhi; 2004 Dec; 42(23):1453-6. PubMed ID: 15733464
[TBL] [Abstract][Full Text] [Related]
16. Genistein induces cell growth inhibition in prostate cancer through the suppression of telomerase activity.
Ouchi H; Ishiguro H; Ikeda N; Hori M; Kubota Y; Uemura H
Int J Urol; 2005 Jan; 12(1):73-80. PubMed ID: 15661057
[TBL] [Abstract][Full Text] [Related]
17. Physiologically achievable concentrations of genistein enhance telomerase activity in prostate cancer cells via the activation of STAT3.
Chau MN; El Touny LH; Jagadeesh S; Banerjee PP
Carcinogenesis; 2007 Nov; 28(11):2282-90. PubMed ID: 17615260
[TBL] [Abstract][Full Text] [Related]
18. Upregulation of manganese superoxide dismutase (SOD2) is a common pathway for neuroendocrine differentiation in prostate cancer cells.
Quirós I; Sáinz RM; Hevia D; García-Suárez O; Astudillo A; Rivas M; Mayo JC
Int J Cancer; 2009 Oct; 125(7):1497-504. PubMed ID: 19507253
[TBL] [Abstract][Full Text] [Related]
19. Epidermal growth factor-induced neuroendocrine differentiation and apoptotic resistance of androgen-independent human prostate cancer cells.
Humez S; Monet M; Legrand G; Lepage G; Delcourt P; Prevarskaya N
Endocr Relat Cancer; 2006 Mar; 13(1):181-95. PubMed ID: 16601287
[TBL] [Abstract][Full Text] [Related]
20. A human- and male-specific protocadherin that acts through the wnt signaling pathway to induce neuroendocrine transdifferentiation of prostate cancer cells.
Yang X; Chen MW; Terry S; Vacherot F; Chopin DK; Bemis DL; Kitajewski J; Benson MC; Guo Y; Buttyan R
Cancer Res; 2005 Jun; 65(12):5263-71. PubMed ID: 15958572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
